24/7 Market News Snapshot 14 October, 2025 – Celularity Inc. Class A Common Stock (NASDAQ:CELU)

October 14, 2025

DENVER, Colo., 14 October, 2025 (www.247marketnews.com) – (NASDAQ:CELU) are discussed in this article.
Celularity Inc. is experiencing a positive surge in pre-market trading, currently positioned at $2.093, reflecting a 2.60% increase from the previous closing price of $2.040. This uptick is complemented by a substantial trading volume of 1.04 million shares, indicating a robust interest from investors which could signal potential momentum for the stock. Technical indicators appear to support this upward movement, with moving averages hinting at bullish trends. Continued adherence to this trajectory, alongside sustained volumes, may foster increased bullish sentiment among market participants. It is advisable for investors to monitor key resistance and support levels to strategically evaluate entry and exit points in the near term.

In addition to its stock performance, Celularity is making significant strides in regenerative medicine with the announcement of promising results from a Phase 2 clinical trial for its novel therapy targeting diabetic foot ulcers (DFUs) complicated by peripheral artery disease (PAD). The findings, recently published in the International Wound Journal, highlight PDA-002, a placenta-derived cell therapy, and its potential efficacy in treating chronic DFUs.

The trial engaged 159 adults, demonstrating that PDA-002 is safe and highly effective; notably, the lower dosage achieved a 38.5% complete wound closure rate in PAD patients, surpassing the 22.6% closure rate observed in the placebo group. This innovative treatment addresses a significant gap in currently FDA-approved therapies for DFUs and PAD, further emphasizing the urgency for advanced therapeutic options in wound care.

Robert J. Hariri, M.D., Ph.D., the Chairman and CEO of Celularity, noted that the findings underscore the regenerative potential of PDA-002, positioning the company to advance towards a confirmatory Phase 3 trial. Furthermore, upcoming legislation set to take effect on July 1, 2025, will facilitate the use of PDA-002 by licensed physicians in specific regions, enhancing patient access to essential treatment options. Celularity’s dedication to addressing critical healthcare needs underscores its leadership in regenerative medicine, offering hope to millions affected by chronic diabetic conditions.

Related news for (CELU)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.